Advantage Austria Show navigation
We think you are in the USAGo to this country pageChange country

GENSPEED Biotech develops a rapid testing system for hospital-acquired infections

2017.09.12

The Austrian start-up develops, manufactures and markets rapid diagnostic tests to detect a range of pathogens.

Contagion with antibiotic-resistant bacilli acquired during hospital stays or infections with periodontitis pathogens can have serious consequences for patients, as well as causing additional annual costs that can run into millions. Identification of both hospital germs and periodontitis pathogens in dental work can take many days, as samples have previously needed to be investigated in a series of laborious analytical tests.

GENSPEED has been developed as a universal rapid testing technology that will prove a boon to both doctors and patients. GENSPEED Biotech ’s quick assays allow a range of hospital germs to be identified in an in-house laboratory in less than 100 minutes, while periodontitis pathogens can be pinpointed in a dental practice in only 20 minutes.

Speedy diagnosis makes it possible to begin targeted treatment immediately and automation also saves users time and expense. The security and accuracy of test results is also improved, and the products have already been used successfully in both hospitals and dental practices.

GENSPEED Biotech was founded in 2016 as a spin-off of the medical technology company Greiner Bio-One and is dedicated to developing, manufacturing and marketing rapid diagnostic assays to detect a range of different pathogens.

Last modified
2017.09.07
print
©©ADVANTAGE AUSTRIA